bacille calmette-guerin + purified protein derivative

This is a **combination** of **bacille Calmette-Guérin (BCG)**, a live attenuated vaccine derived from *Mycobacterium bovis*, and **purified protein derivative (PPD)**, a standardized preparation of tuberculin proteins. BCG is used primarily as a vaccine for the prevention of tuberculosis and for immunotherapy in conditions such as bladder cancer. PPD is used for the tuberculin skin test (Mantoux test) to detect *Mycobacterium tuberculosis* infection. This combination may refer to research or clinical protocols where both BCG and PPD are used together to evaluate immune responses, optimize vaccine strategies, or assess synergistic effects in tuberculosis prophylaxis and treatment contexts. BCG works by inducing a complex cell-mediated immune response against mycobacterial antigens, activating T cells (CD4+, CD8+), and NK cells, resulting in heightened IFN-γ and cytokine production. PPD acts primarily as a diagnostic immunostimulant, eliciting a delayed-type hypersensitivity reaction in individuals previously sensitized to mycobacterial proteins. There is no evidence that this combination is a routine pharmaceutical product or approved combination drug; it appears primarily as a co-administration or research tool[1][2][3].